uniQure N.V. $QURE Shares Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd lifted its position in shares of uniQure N.V. (NASDAQ:QURE) by 148.9% in the first quarter, Holdings Channel reports. The institutional investor owned 113,952 shares of the biotechnology company’s stock after acquiring an additional 68,174 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in uniQure were worth $1,863,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. grew its position in uniQure by 5.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after acquiring an additional 533 shares during the period. Arizona State Retirement System raised its position in uniQure by 6.0% in the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 627 shares during the period. Ensign Peak Advisors Inc lifted its stake in shares of uniQure by 21.7% in the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 650 shares during the last quarter. FNY Investment Advisers LLC lifted its stake in shares of uniQure by 76.7% in the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 718 shares during the last quarter. Finally, CIBC Private Wealth Group LLC purchased a new position in shares of uniQure during the 3rd quarter worth $50,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at uniQure

In other news, CEO Matthew C. Kapusta sold 21,082 shares of uniQure stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $45.16, for a total value of $952,063.12. Following the transaction, the chief executive officer directly owned 519,227 shares of the company’s stock, valued at $23,448,291.32. The trade was a 3.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total transaction of $526,526.10. Following the completion of the sale, the director owned 43,254 shares of the company’s stock, valued at approximately $1,949,025.24. This trade represents a 21.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 433,229 shares of company stock valued at $17,944,799 over the last ninety days. 4.65% of the stock is owned by insiders.

uniQure Stock Performance

Shares of QURE stock opened at $44.48 on Friday. The company has a market cap of $2.81 billion, a P/E ratio of -12.78 and a beta of 0.90. The firm has a fifty day moving average price of $32.51 and a 200 day moving average price of $24.43. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. The company had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. Sell-side analysts predict that uniQure N.V. will post -3.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on QURE shares. Cantor Fitzgerald upgraded shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective on the stock in a report on Wednesday, June 17th. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Royal Bank Of Canada boosted their target price on uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday, June 18th. Stifel Nicolaus set a $28.00 price target on uniQure in a research report on Tuesday, May 5th. Finally, Leerink Partners boosted their price objective on uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $64.17.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.